While diagnostics start-ups have delivered good returns to private investors, they've performed miserably for the public, with a few significant exceptions. In this statistical review, we segment the industry, showing the trends that have won with investors (automation, drug-focused diagnostics) and those that have lost big (point-of-care testing).